Molecular analysis showed that the tumor tissue, composed solely of rhabdoid cells, also harbored a BRAF V600E mutation and homozygous CDKN2A deletion, molecular signatures of PXA, along with loss of INI1 expression. The gene discussed is CDKN2A; the disease is neoplasm.